Erythema Infectiosum: clinical case

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Human Parvovirus B19 has been recognized as the causative agent of a wide range of diseases. The cellular receptorfor parvovirus B19 is P antigen located on the trophoblast cells, bone marrow, liver, kidney, synovium, etc. has been associated with many clinical situations, erythema infectiosum and erythroblastopenia crisis. In the absence of P-antigen, revealed no susceptibility to parvovirus infection. Infection in pregnant women under 20 weeks gestation can lead to miscarriage or non-immune hydrops, fetal death. 1-5% of women are susceptible to parvovirus infection during pregnancy. Viral infection may be responsible for aplastic anaemia in immuno-compromised patients. Diagnosis ofparvovirus infection B19 is based on the results of general blood analysis; biochemical analysis of blood; serological methods, PCR detection of IgM, immunoblot IgM/IgG. The most common clinicalform of parvovirus B19 infection in children is erythema infectiosum. It is also called “fifth disease”. Erythema infectiosum is characterized by a viral prodrome followed by the “slapped cheek’ facial rash and macula papular lace or mesh rash on the skin of the trunk and extensor surfaces.

Full Text

Restricted Access

About the authors

Albina G. Pashinyan

N.I. Pirogov Russian National Research Medical University

Email: stsoagp4@gmail.com
MD, PhD, DSc, prof. of N.I. Pirogov Russian National Research Medical University Moscow, 117997, Russian Federation

N. K Runikhina

N.I. Pirogov Russian National Research Medical University

Russian Scientific Clinical Center of Gerontology Moscow, 117997, Russian Federation

E. Yu Mokeeva

N.I. Pirogov Russian National Research Medical University

Russian Scientific Clinical Center of Gerontology Moscow, 129226, Russian Federation

References

  1. Cossart Y.E., Field A.M., Cant B., Widdows D. Parvovirus-like particles in human sera. Lancet. 1975; 11(1): 72-3.
  2. Norja P., Lassila R., Makris M. Parvovirus transmission by blood products - a cause for concern? Br. J. Haematol. 2012; 159(4): 385-93.
  3. Servant-Delmas A., Lefrère J.J., Morinet F., Pillet S. Advances in human B19 erythrovirus biology. J. Virol. 2010; 84(19): 9658-65.
  4. Blumel J., Burger R., Drosten C., Groner A., Gurtler L., Heiden M., et al. Parvovirus B19 - Revised. Transfus. Med. Hemother. 2010; 37(6): 339-50.
  5. Candotti D., Etiz N., Parsyan A., Allain J.P. Identification and characterization of persistent human erythrovirus infection in blood donor samples. J. Virol. 2004; 78(22): 12169-78.
  6. Parsyan A., Szmaragd C., Allain J.P., Candotti D. Identification and genetic diversity of two human parvovirus B19 genotype 3 subtypes. J. Gen. Virol. 2007; 88(2): 428-31.
  7. Filippone C., Zhi N., Wong S., Lu J., Kajigaya S., Gallinella G., et al. VP1u phospholipase activity is critical for infectivity of full-length parvovirus B19 genomic clones. Virology. 2010; 374(2): 444-52. doi: 10.1016/j.virol.2008.01.002.
  8. Anderson L.J., Tsou C., Parker R.A., Chorba T.L., Wulff H., Tattersall P., Mortimer P.P. Detection of antibodies and antigens of human parvovirus B19 by enzyme-linked immunosorbent assay. J. Clin. Microbiol. 1986; 24(4): 522-6.
  9. Marano G., Vaglio S., Pupella S., Facco G., Calizzani G., Candura F., et al. Human Parvovirus B19 and blood product safety: a tale of twenty years of improvements. Blood Transfus. 2015; 13(2): 184-96. doi: 10.2450/2014.0174.14.
  10. Lamont R.F., Sobel J.D., Vaisbuch E., Kusanovic J.P., Mazaki-Tovi S., Kim S.K., et al. Parvovirus B19 infection in human pregnancy. BJOG. 2011; 118(2): 175-86. doi: 10.1111/j.1471-0528.2010.02749.x.
  11. Subtil D., Garabedian C., Chauvet A. Parvovirus B19 infection and pregnancy. Presse Med. 2015; 44(6, Pt 1): 647-53. doi: 10.1016/j.lpm.2015.04.013.
  12. Enders M., Klingel K., Weidner A., Baisch C., Kandolf R., Schalasta G., Enders G. Risk of fetal hydrops and non-hydropic late intrauterine fetal death after gestational parvovirus B19 infection. J. Clin. Virol. 2010; 49(3): 163-8. doi: 10.1016/j.jcv.2010.07.014.
  13. de Jong E., Walther F., Kroes A., Oepkes D. Parvovirus B19 infection in pregnancy: new insights and management. Prenat. Diagn. 2011; 31(5): 419-25. doi: 10.1002/pd.2714.
  14. Shabani Z., Esghaei M., Keyvani H., Shabani F., Sarmadi F., Mollaie H., Monavari S.H. Relation between parvovirus B19 infection and fetal mortality and spontaneous abortion. Med. J. Islam. Repub. Iran. 2015; 7(29): 197.
  15. Dingli D., Pfizenmaier D.H., Arromdee E., Wennberg P., Spittell P.C., Chang-Miller A., Clarke B.L. Severe digital arterial occlusive disease and acute parvovirus B19 infection. Lancet. 2000; 356(9226): 312-4. doi: 10.1016/S0140-6736(00)02512-5.
  16. Kerr J.R. Pathogenesis of human parvovirus B19 in rheumatic disease. Ann. Rheum. Dis. 2000; 59(9): 672-83. doi: 10.1136/ard.59.9.672.
  17. Bock C.T., Duchting A., Utta F., Brunner E., Sy B.T., Klingel K., et al. Molecular phenotypes of human parvovirus B19 in patients with myocarditis. World J. Cardiol. 2014; 6(4): 183-95. doi: 10.4330/wjc.v6.i4.183.
  18. Tesapirat L., Wanlapakorn N., Chieochansin T., Poovorawan Y. Parvovirus b19 infection presenting as acute hepatitis and transient anemia in a previously healthy child. Southeast Asian J. Trop. Med. Public Health. 2015; 46(2): 226-30.
  19. Peterlana D., Puccetti A., Corrocher R., Lunardi C. Serologic and molecular detection of human parvovirus B19 infection. Clin. Chim. Acta. 2006; 372(1-2): 14-23.
  20. Koppelman M.H., van Swieten P., Cuijpers H.T. Real-time polymerase chain reaction detection of parvovirus B19 DNA in blood donations using a commercial and an in-house assay. Transfusion. 2011; 51(6): 1346-54. doi: 10.1111/j.1537-2995.2010.02995.x.
  21. Juhl D., Gorg S., Hennig H. Persistence of parvovirus B19 (B19V) DNA and humoral immune response in B19V-infected blood donors. Vox Sang. 2014; 107(3): 226-32. doi: 10.1111/vox.12162.
  22. Bonjoch X., Obispo F., Alemany C., Pacha A., Rodriguez E., Xairo D. Characterization of markers of the progression of human parvovirus B19 infection in virus DNA-positive plasma samples. Transfus. Med. Hemother. 2015; 42(4): 233-8. doi: 10.1159/000381979.
  23. Nadimpalli S.S., Miller R.S., Kamath V.M., Farkouh C.R., Nhan-Chang C.L., Rathe J.A., et al. Congenital parvovirus B19 infection: persistent viremia and red blood cell aplasia. Open Forum Infect. Dis. 2015; 2(2): ofv049. doi: 10.1093/ofid/ofv049.
  24. Bonvicini F., Puccetti C., Salfi N.C., Guerra B., Gallinella G., Rizzo N., et al. Gestational and fetal outcomes in B19 maternal infection: a problem of diagnosis. J. Clin. Microbiol. 2011; 49(10): 3514-8. doi: 10.1128/JCM.00854-11.
  25. Allmon A., Deane K., Martin K.L. Common skin rashes in children. Am. Fam. Physician. 2015; 92(3): 211-6.
  26. Drago F., Ciccarese G., Broccolo F., Javor S., Parodi A. Atypical exanthems associated with Parvovirus B19 (B19V) infection in children and adults. J. Med. Virol. 2015; 87(11): 1981-4. doi: 10.1002/jmv.24246.

Statistics

Views

Abstract: 164

Dimensions

Article Metrics

Metrics Loading ...

PlumX


Copyright (c) 2016 Eco-Vector



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies